Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Maandag 31-01-2011

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,893   +0,020   (+2,23%) Dagrange 0,884 - 0,901 3.728.995   Gem. (3M) 6,5M

Maandag 31-01-2011

Volgen
214 Posts
Pagina: «« 1 ... 6 7 8 9 10 11 | Laatste | Omlaag ↓
  1. [verwijderd] 31 januari 2011 23:38
    Leiden, The Netherlands, August 10, 2006. Biotech company Pharming Group NV (“Pharming”) (Euronext: PHARM) (PHARM.AS) today announced that it will proceed with the acquisition of DNage BV (“DNage”) based on a decision by the Enterprise Section of the Amsterdam Court of Appeal (“Enterprise Section”).

    The Enterprise Section has rejected the appeal of the Works Council regarding the proposed acquisition of DNage. The decision allows Pharming and DNage to proceed with the acquisition, which will now be finalized as originally planned. Pharming expects the legal agreements and other formalities necessary for the acquisition to be completed in the near future.

    On March 24, 2006, Pharming announced a heads of agreement with DNage to acquire all shares of DNage. During the acquisition process, the Works Council of Pharming, however, appealed the decision to acquire DNage at the Enterprise Section.

    A combination of Pharming with DNage will generate important synergies. It will provide Pharming with access to highly innovative products and a technology platform for new markets in the areas of ageing and cancer. The combination of the world-class technology owned and in-licensed by DNage and Pharming's human protein products will provide Pharming with new opportunities in the area of tissue repair and regeneration. Pharming expects the acquisition of DNage to trigger additional business development opportunities including new partnerships as well as grants and subsidies.

    Pharming remains committed to bringing recombinant human C1 inhibitor and human lactoferrin to the market through focused efforts in the shortest time possible. At the same time, Pharming will continue to build on its research efforts creating a sustainable portfolio of products and technologies addressing markets with significant medical needs.

    Background on DNage BV
    DNage is a biopharmaceutical company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The company was funded through an equity investment of an international syndicate of venture capitalists consisting of Life Sciences Partners (NL) and Inventages (CH). The company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of aging, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of aging, leveraging the unique technologies developed by its founders. On April 24, 2006, DNage announced the start of a corporate partnership with Loders Croklaan BV and BG Medicine Inc in the field of type II Diabetes. This program is supported with a € 1 million grant awarded by the Dutch Department of Economic Affairs. Additional information is available on the DNage website www.dnage.nl.

    Background on Pharming Group NV
    Pharming Group N.V. is developing innovative protein products for unmet needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for food use. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, www.pharming.com.

    This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

    Contact:
    Carina Hamaker, Investor Voice (NL), T: +31 (0)6 537 49959 or +31 (0)71 524 7431
    Sarah MacLeod, Financial Dynamics (UK), T: +44 (0)20 7269 7148 or +44 (0)7747 602 739
    Samir Singh, Pharming Group NV (US), T: +1 908 720 6224 or +1 800 333 1476
    Rein Strijker, DNage BV, T: +31 (0)6 539 12661
  3. [verwijderd] 31 januari 2011 23:40
    quote:

    TechN9ne schreef op 31 januari 2011 23:24:

    Aan deze info hebben we genoeg!!!

    Pharming staakt financiering DNage
    31-1-2011 17:12:00


    Pharming Group NV
    0,191 ( 17:39 ) -0,0050 / -2,55%



    AMSTERDAM (Dow Jones)--Pharming Group nv (PHARM.AE) is gestopt met het financieren van het vorig jaar afgesplitste onderdeel DNage, maakt het bedrijf maandag bekend.

    Bij de spin-off in juli 2010 van DNage kwam Pharming overeen om DNage tijdelijk te voorzien van een beperkt overbruggingskrediet, waarvan de hoogte niet bekend is gemaakt. Het krediet was bedoeld om DNage tijd te geven nieuwe investeerders te zoeken.

    Pharming meldt nu dat DNage er niet in is geslaagd om nieuwe investeerders te vinden en daarom hebben de aandeelhouders van DNage nu gekozen voor vrijwillige liquidatie.



    "Daarom hebben de aandeelhouders van DNage nu gekozen tot vrijwillige liquidatie".
    -onder die aandeelhouders is dus ook pharming.
    -terugkoop na liquidatie door Pharming?

    Door Levien de Feijter; Dow Jones Nieuwsdienst +31 20 57 15 201; levien.defeijter@dowjones.com

    Tech




  4. [verwijderd] 31 januari 2011 23:42
    quote:

    Robertus Nurks schreef op 31 januari 2011 23:38:

    Leiden, The Netherlands, August 10, 2006. Biotech company Pharming Group NV (“Pharming”) (Euronext: PHARM) (PHARM.AS) today announced that it will proceed with the acquisition of DNage BV (“DNage”) based on a decision by the Enterprise Section of the Amsterdam Court of Appeal (“Enterprise Section”).

    The Enterprise Section has rejected the appeal of the Works Council regarding the proposed acquisition of DNage. The decision allows Pharming and DNage to proceed with the acquisition, which will now be finalized as originally planned. Pharming expects the legal agreements and other formalities necessary for the acquisition to be completed in the near future.

    On March 24, 2006, Pharming announced a heads of agreement with DNage to acquire all shares of DNage. During the acquisition process, the Works Council of Pharming, however, appealed the decision to acquire DNage at the Enterprise Section.

    A combination of Pharming with DNage will generate important synergies. It will provide Pharming with access to highly innovative products and a technology platform for new markets in the areas of ageing and cancer. The combination of the world-class technology owned and in-licensed by DNage and Pharming's human protein products will provide Pharming with new opportunities in the area of tissue repair and regeneration. Pharming expects the acquisition of DNage to trigger additional business development opportunities including new partnerships as well as grants and subsidies.

    Pharming remains committed to bringing recombinant human C1 inhibitor and human lactoferrin to the market through focused efforts in the shortest time possible. At the same time, Pharming will continue to build on its research efforts creating a sustainable portfolio of products and technologies addressing markets with significant medical needs.

    Background on DNage BV
    DNage is a biopharmaceutical company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The company was funded through an equity investment of an international syndicate of venture capitalists consisting of Life Sciences Partners (NL) and Inventages (CH). The company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of aging, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of aging, leveraging the unique technologies developed by its founders. On April 24, 2006, DNage announced the start of a corporate partnership with Loders Croklaan BV and BG Medicine Inc in the field of type II Diabetes. This program is supported with a € 1 million grant awarded by the Dutch Department of Economic Affairs. Additional information is available on the DNage website www.dnage.nl.

    Background on Pharming Group NV
    Pharming Group N.V. is developing innovative protein products for unmet needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for food use. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, www.pharming.com.

    This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

    Contact:
    Carina Hamaker, Investor Voice (NL), T: +31 (0)6 537 49959 or +31 (0)71 524 7431
    Sarah MacLeod, Financial Dynamics (UK), T: +44 (0)20 7269 7148 or +44 (0)7747 602 739
    Samir Singh, Pharming Group NV (US), T: +1 908 720 6224 or +1 800 333 1476
    Rein Strijker, DNage BV, T: +31 (0)6 539 12661
    Een bericht uit 2006, was dat nog in de tijd van aap noot mies zus?
    Het is 2011 :-)
  5. [verwijderd] 31 januari 2011 23:43
    Leiden, The Netherlands, June 8, 2006. Biotech company Pharming Group NV (“Pharming” or “the Company”) (Euronext: PHARM) (PHARM.AS) provided today an update on the acquisition of DNage BV (“DNage”). On March 24, 2006, Pharming announced that it had reached an agreement in principle with DNage under which Pharming will acquire all shares of DNage.

    The completion and signing of the final sale and purchase agreement was expected by the end of May 2006 pending the fulfillment of a number of conditions, including the obtaining of all necessary corporate approvals. During the acquisition process, the Works Council (“Ondernemingsraad”) of Pharming provided a negative advice on the acquisition, citing an incorrect procedure of employee consultation and insufficient motivation for the decision to acquire DNage. It has announced that it will appeal the decision to acquire DNage at the Enterprise Chamber (“Ondernemingskamer”). The eventual implementation of the sale and purchase agreement will be dependent on the outcome of that appeal.

    Pharming hopes that the outcome of the appeal will be positive as it believes that a combination of Pharming with DNage will generate important synergies. It will provide Pharming with access to highly innovative products and a technology platform for new markets in the areas of ageing and cancer. The combination of the world-class technology owned and in-licensed by DNage and Pharming's human protein products will provide Pharming with new opportunities in the area of tissue repair and regeneration. Management of Pharming is convinced that DNage's business will contribute greatly to the value of Pharming, through the obvious synergies as well as through the identification of new product leads in important markets.

    Pharming remains committed to bringing recombinant human C1 inhibitor and human lactoferrin to the market through focused efforts in the shortest time possible. At the same time, the Company will continue to build on its research efforts creating a sustainable portfolio of products and technologies. Pharming expects the acquisition of DNage to trigger additional business development opportunities including new partnerships as well as grants and subsidies. The latter is exemplified by the recent announcement of a corporate partnership between DNage, LodersCroklaan and BG-Medicine, subsidized by the Netherlands Department of Economic Affairs.

    Background on DNage BV
    DNage is a biopharmaceutical company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was funded through an equity investment of an international syndicate of venture capitalists consisting of Life Sciences Partners (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of aging, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of aging, leveraging the unique technologies developed by its founders. On April 24, 2006, DNage announced the start of a corporate partnership with LodersCroklaan and BG-Medicine in the field of type II Diabetes. This program is supported with a 1 million Euro grant awarded by the Dutch Department of Economic Affairs. Additional information is available on the DNage website www.dnage.nl.

    Background on Pharming Group NV
    Pharming Group NV is developing innovative protein products for unmet needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for food use. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, www.pharming.com.

    This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.
  8. [verwijderd] 31 januari 2011 23:46
    Leiden, The Netherlands, December 29, 2005. Biotech company Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM) (PHARM.AS) announced today that it has completed its human lactoferrin (hLF) filing for a Generally Recognized as Safe (GRAS) notification with the US Food and Drug Administration (FDA).

    Pharming has notified the FDA that its hLF is generally recognized as safe for use as an ingredient in functional foods. Pharming's hLF GRAS notification has been reviewed by an independent scientific expert panel. After careful evaluation of numerous safety studies performed with Pharming's hLF as well as of published scientific data, the expert panel has concluded that hLF is safe for its intended uses.

    "Pharming is pleased with the progress on the development of hLF," said Dr. Francis Pinto, CEO of Pharming. 'The Company is in a strong position to execute commercial agreements and is ready for a new phase of rapid corporate growth."

    Background on Pharming Group N.V.
    Pharming Group N.V. is developing innovative protein products for unmet needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for use in functional foods. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, www.pharming.com.

    This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.
  12. [verwijderd] 31 januari 2011 23:55
    Hoopmazzel:
    "Daarom hebben de aandeelhouders van DNage nu gekozen tot vrijwillige liquidatie".
    -onder die aandeelhouders is dus ook pharming.
    -terugkoop na liquidatie door Pharming?"
    -----------------------------------------------

    Precies Mazzel, Pharming zal zelfs de grootste vinger in de pap gehad hebben bij die beslissing.
    Maar jij denkt toch niet echt dat een moederbedrijf dat zelf niet in staat is een normaal bankkrediet los te peuteren in staat zal zijn ook maar iets terug te kopen ( dat vermoedelijk ook nauwelijks waarde heeft ,gezien de interesse!)
    Verder: volgens onze doedelzakspeler heeft Pharming trouwens alles al afgeschreven (geloof hem toch maar niet helemaal hoor)

    Welterusten!

214 Posts
Pagina: «« 1 ... 6 7 8 9 10 11 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. CEO: Pharming koopt met KL1333 van Abliva goede kans op blockbuster (video)
  2. RBC verhoogt koersdoel Pharming fors
  3. Afwachtend begin van Super Central Bank-week en we hebben een beursganger
  4. CEO De Vries: Pharming dicht bij overname van nieuwe blockbuster
  5. Pharming brengt bod op Abliva AB uit
  6. Moeizame week voor financials
  7. Weekoverzicht: vastgoed uit de gratie, winst voor automotive en chipaandelen
  8. Fundlogic verkleint belang in Pharming
  9. Fundlogic meldt belang in Pharming
  10. Jefferies: positieve studiedata Pharming vergroten doelgroep Joenja